Online pharmacy delivery moves HIV prevention into the digital checkout lane
Kenya is testing a different route for HIV prevention: daily oral pre-exposure prophylaxis and post-exposure prophylaxis delivered through an online pharmacy rather than a conventional clinic visit. The ePrEP Kenya pilot study will use MYDAWA, a private online retailer, to identify adults at risk for HIV in Nairobi, guide them through self-screening, and link them to telemedicine-based prescribing. The model is built around a simple clinical problem. Many people who could benefit from PrEP or PEP do not regularly present to health facilities, even when online sexual and reproductive health products are already part of their lives.
The protocol is designed for an 18-month pilot and focuses on what happens when HIV prevention is placed inside a digital purchasing pathway. Potential clients first encounter information on MYDAWA’s sexual wellness page and then complete a self-screening tool for HIV risk. Adults 18 years and older who are judged to be at risk and who are willing to pay for both a blood-based HIV self-test and delivery are eligible to enter the pathway. In practical terms, the system asks users to move from anonymous digital interest to a more formal prevention evaluation without requiring an initial in-person clinic encounter.
A brief line captures the stakes: prevention fails when access is too cumbersome for the people who need it most.
Self-testing, telemedicine, and pharmacy fulfillment form the clinical sequence
The initiation pathway is deliberately structured to preserve HIV safety checks while reducing friction. Eligible participants purchase a blood-based HIV self-test for 250 Kenyan shillings, or about 2 US dollars, and can have it delivered for 99 Kenyan shillings, or about 1 US dollar, to a setting of their choice. They then upload an image of the result and attend a telemedicine visit with a MYDAWA provider. During that visit, clinicians review the self-test result, assess PrEP or PEP eligibility, and screen for medical concerns such as kidney disease. Counseling on use and safety is part of the encounter, not an add-on.
This design reflects how PrEP and PEP should work biologically as well as operationally. PrEP is only useful if the patient is HIV-negative at initiation and understands how to sustain adherence over time; PEP depends on fast access after exposure, when the window for interruption of viral establishment is short. By combining self-testing with telemedicine review, the pilot aims to preserve those core safeguards while shifting the first point of contact away from a clinic queue. The clinical logic is straightforward: if the pathway can identify risk, confirm HIV-negative status, and triage medical exclusions, then online dispensing becomes more than convenience — it becomes a service delivery strategy.
When clients are found to be HIV positive on self-test, or when they report existing medical conditions, MYDAWA providers refer them to appropriate healthcare facilities based on the client’s preferences. That referral step is crucial because online delivery cannot replace evaluation for active HIV infection or unmanaged comorbidity. It can, however, push people toward the right next step faster than a conventional system that depends on repeated facility attendance.
What the pilot will measure in real-world use
The study is not framed as a clinical efficacy trial in the usual sense. Instead, it is an implementation pilot that will measure whether this model can actually function at scale for people seeking HIV prevention in Nairobi. The primary outcomes include PrEP initiation among eligible clients, PEP initiation, transition from PEP to PrEP, and PrEP continuation. The investigators will also examine feasibility, acceptability, and costs.
Those outcomes matter because online delivery of prophylaxis raises questions that do not appear in a standard clinic workflow. Will users complete self-testing correctly? Will they upload results reliably? Will telemedicine visits provide enough clinical oversight to catch contraindications such as renal disease? Will clients remain engaged long enough to continue daily oral prophylaxis after the first prescription? Each of those questions maps to a potential break in the chain between interest and protection.
The transition from PEP to PrEP deserves particular attention. PEP is meant for short-term use after an exposure, but people with ongoing risk may need to move rapidly into ongoing PrEP. An online pharmacy model could make that handoff easier because the same digital platform, provider network, and delivery system can carry the patient from acute prevention to maintenance prevention. If the process works, it could reduce the delay that often occurs when a person finishes PEP and must navigate a separate clinic pathway to continue protection.
Why this model matters in a high-prevalence setting
The rationale for the pilot is anchored in the persistent challenge of HIV transmission in settings with substantial background prevalence. Expanding access to both PrEP and PEP is not simply a matter of adding another prescribing channel. It is a way of reaching adults who already use e-commerce platforms for private sexual and reproductive health needs and who may prefer a discreet, remote route to prevention. That privacy may be especially relevant for people who avoid health facilities because of stigma, scheduling constraints, travel burdens, or concerns about being recognized.
Online pharmacies already distribute related products such as HIV self-tests and contraception in Kenya. The pilot leverages that existing behavior and asks whether prophylaxis can be layered onto it safely. The biological target is the same as in clinic-based care: reduce the chance that exposure becomes established infection. The difference lies in access architecture. Instead of depending on a face-to-face intake, the program uses self-screening, home or preferred-location delivery, a digital proof-of-testing step, and a telemedicine consult before prescribing.
If the model proves feasible and acceptable, it could help inform Kenya’s guidelines and offer a template for similar settings. But the unresolved questions are operational, not abstract. Can a private online pharmacy reliably identify the right patients, verify HIV-negative status, screen out contraindications, and maintain adherence long enough to matter? Can the platform support safe and timely referral when a self-test is positive or medical complexity emerges? The pilot is built to answer those questions with implementation data rather than assumptions, and the results will determine whether online HIV prophylaxis can move from a promising concept to a durable part of prevention delivery.